177 related articles for article (PubMed ID: 37084131)
1. Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features.
Lorusso L; Minaldi E; Esposito G; Piaggi P; Bottici V; Brogioni S; Giani C; Valerio L; Molinaro E; Elisei R; Agate L
J Endocrinol Invest; 2023 Oct; 46(10):2165-2173. PubMed ID: 37084131
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
3. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.
Schubert L; Mbekwe-Yepnang AM; Wassermann J; Braik-Djellas Y; Jaffrelot L; Pani F; Deniziaut G; Lussey-Lepoutre C; Chereau N; Leenhardt L; Bernier MO; Buffet C
J Endocrinol Invest; 2024 Jun; 47(6):1573-1581. PubMed ID: 38578580
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer.
Yu Q; Zhang X; Li L; Zhang C; Huang J; Huang W
Asia Pac J Clin Oncol; 2023 Jun; 19(3):279-289. PubMed ID: 35950297
[TBL] [Abstract][Full Text] [Related]
6. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Meng C; Song J; Long W; Mu Z; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2023; 14():1109439. PubMed ID: 36843580
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
8. Can 99 Tc m -3PRGD 2 (α ν β 3 ) and 18 F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: Case report.
Zhang Y; Li Y; Lin Z; Chen W
Medicine (Baltimore); 2023 Feb; 102(5):e32751. PubMed ID: 36749225
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
10. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
[TBL] [Abstract][Full Text] [Related]
11. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer.
Cheng X; Xu S; Zhu Y; Wu J; Bao J; Yu H; Zhang L
Eur J Clin Invest; 2022 Apr; 52(4):e13721. PubMed ID: 34855206
[TBL] [Abstract][Full Text] [Related]
12. Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults.
Tian T; Huang S; Dai H; Qi M; Liu B; Huang R
J Clin Endocrinol Metab; 2023 Jan; 108(2):306-314. PubMed ID: 36226635
[TBL] [Abstract][Full Text] [Related]
13. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
14. Metabolomic screening of radioiodine refractory thyroid cancer patients and the underlying chemical mechanism of iodine resistance.
Zheng W; Tang X; Dong J; Feng J; Chen M; Zhu X
Sci Rep; 2024 May; 14(1):10546. PubMed ID: 38719979
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
16. Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
de la Fouchardière C; Godbert Y; Dalban C; Illouz F; Wassermann J; Do Cao C; Bardet S; Zerdoud S; Chougnet CN; Zalzali M; Benisvy D; Niccoli P; Digue L; Lamartina L; Schwartz P; Borson Chazot F; Gautier J; Pérol D; Leboulleux S;
Eur J Cancer; 2021 Nov; 157():153-164. PubMed ID: 34509954
[TBL] [Abstract][Full Text] [Related]
17. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
de la Fouchardiere C; Oussaid N; Derbel O; Decaussin-Petrucci M; Fondrevelle ME; Wang Q; Bringuier PP; Bournaud-Salinas C; Peix JL; Lifante JC; Giraudet AL; Lopez J; Borson-Chazot F
Target Oncol; 2016 Feb; 11(1):71-82. PubMed ID: 26285789
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound characteristics of cervical lesions in patients with radioiodine refractory differentiated thyroid cancer: A strobe-compliant article.
Gao L; Lin Y; Jiang Y; Li H; Gao Q; Xi X; Wang Y; Yang X; Lai X; Zhu S; Zhang X; Zhao R; Zhang B
Medicine (Baltimore); 2019 Nov; 98(45):e17876. PubMed ID: 31702656
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
20. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
Satapathy S; Bal C
Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
